Evaluation of direct oral anticoagulant reversal agents in intracranial hemorrhage: a systematic review and meta-analysis
R Chaudhary, A Singh, R Chaudhary… - JAMA Network …, 2022 - jamanetwork.com
Importance Direct oral anticoagulant (DOAC)–associated intracranial hemorrhage (ICH) has
high morbidity and mortality. The safety and outcome data of DOAC reversal agents in ICH …
high morbidity and mortality. The safety and outcome data of DOAC reversal agents in ICH …
The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation
JG Andrade, M Aguilar, C Atzema, A Bell… - Canadian Journal of …, 2020 - Elsevier
Abstract The Canadian Cardiovascular Society (CCS) atrial fibrillation (AF) guidelines
program was developed to aid clinicians in the management of these complex patients, as …
program was developed to aid clinicians in the management of these complex patients, as …
Andexanet alfa or prothrombin complex concentrate for factor Xa inhibitor reversal in acute major bleeding: a systematic review and meta-analysis
OBJECTIVES: To combine evidence on andexanet alfa and prothrombin complex
concentrates for factor Xa inhibitor-associated bleeding to guide clinicians on reversal …
concentrates for factor Xa inhibitor-associated bleeding to guide clinicians on reversal …
Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants
A Gómez-Outes, P Alcubilla, G Calvo-Rojas… - Journal of the American …, 2021 - jacc.org
Abstract Background Direct oral anticoagulants (DOACs) have shown a positive benefit-risk
balance in both clinical trials and real-world data, but approximately 2% to 3.5% of patients …
balance in both clinical trials and real-world data, but approximately 2% to 3.5% of patients …
Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage
ML Vestal, K Hodulik, J Mando-Vandrick… - Journal of Thrombosis …, 2022 - Springer
Limited data exists regarding the clinical outcomes of andexanet alfa and four factor
prothrombin complex concentrate (4F-PCC) for reversal of apixaban or rivaroxaban in the …
prothrombin complex concentrate (4F-PCC) for reversal of apixaban or rivaroxaban in the …
Retrospective comparison of andexanet alfa and 4-factor prothrombin complex for reversal of factor Xa-inhibitor related bleeding
VM Stevens, TC Trujillo, TH Kiser… - Clinical and Applied …, 2021 - journals.sagepub.com
The aim of this retrospective study was to compare andexanet alfa and 4-factor prothrombin
complex (4F-PCC) for reversal of factor Xa (FXa)-inhibitor bleeding. Patients that received …
complex (4F-PCC) for reversal of factor Xa (FXa)-inhibitor bleeding. Patients that received …
Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures
PG Bradshaw, SP Keegan, ME Droege… - … : The Journal of …, 2022 - Wiley Online Library
Background Outcomes following andexanet alfa reversal of factor Xa inhibitors in patients
requiring urgent or emergent invasive procedures are lacking. This study aimed to describe …
requiring urgent or emergent invasive procedures are lacking. This study aimed to describe …
Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or …
AR Novak, C Shakowski, TC Trujillo, GC Wright… - Journal of Thrombosis …, 2022 - Springer
Despite evolving evidence, the use of direct oral anticoagulants (DOACs) in patients with
extremes of body weight remains controversial. This study aimed to measure the impact of …
extremes of body weight remains controversial. This study aimed to measure the impact of …
[HTML][HTML] Evaluation of oral factor Xa inhibitor‐associated extracranial bleeding reversal with andexanet alfa
Introduction A reversal agent for factor Xa (FXa) inhibitors, andexanet alfa, was Food and
Drug Administration approved without extensive study of clinical effectiveness, due to an …
Drug Administration approved without extensive study of clinical effectiveness, due to an …
[HTML][HTML] A meta‐analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor–related major bleeding
T Jaspers, K Shudofsky, MV Huisman, K Meijer… - Research and practice …, 2021 - Elsevier
Background Andexanet alfa (andexanet) and prothrombin complex concentrate (PCC) are
both reversal agents for major bleeding in patients using factor Xa inhibitors (FXaIs). Our aim …
both reversal agents for major bleeding in patients using factor Xa inhibitors (FXaIs). Our aim …